The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: Clinical analysis of 279 cases

European Journal of Endocrinology

Volumn 166, Issue 5, 2012, Pages 797-802

  Wang, Min ^a   Mou, Chengzhi ^a   Jiang, Meng ^a   Han, Lizhang ^a   Fan, Shengqiang ^a   Huan, Cheng ^a   Qu, Xin ^a   Han, Tao ^a   Qu, Yuanming ^a   Xu, Guangming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PROLACTIN;

ACROMEGALY; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COARSE FACE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CONTROL; FEMALE; GALACTORRHEA; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROLACTIN; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862114485     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1119     Document Type: Article

References (44)

1. Sherlock M, Woods C & Sheppard MC. Medical therapy in acromegaly. Nature Reviews. Endocrinology 2011 7 291-300. (doi:10.1038/nrendo.2011.42)
2. Chanson P, Salenave S, Kamenicky P, Cazabat L & Young J. Pituitary tumours: acromegaly. Best Practice & Research. Clinical Endocrinology & Metabolism 2009 23 555-574. (doi:10.1016/j.beem.2009.05.010)
3. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J & Voutilainen E. A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4081-4086. (doi:10.1210/jc.2004-1381)
4. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM & Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains underrecognized and under-diagnosed. Clinical Endocrinology 2010 72 203-208. (doi:10.1111/j.1365-2265.2009.03626.x)
5. Colao A, Marzullo P, Di Somma C & Lombardi G. Growth hormone and the heart. Clinical Endocrinology 2001 54 137-154. (doi:10.1046/j.1365-2265.2001. 01218.x)
6. Krzentowska-Korek A, Gołkowski F, Bałdys-Waligórska A & Hubalewska-Dydejczyk A. Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 2011 14 157-162. (doi:10.1007/s11102-010- 0273-0)
7. Katznelson L. Approach to the patient with persistent acromegaly after pituitary surgery. Journal of Clinical Endocrinology and Metabolism 2010 95 4114-4123. (doi:10.1210/jc.2010-0670)
8. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Moroni C, Lenzi J, Tamburrano G, Cassone R & Cantore G. Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients. Acta Neurochirurgica 2001 143 1205-1211. (doi:10.1007/s007010100015)
9. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
10. Ben-Shlomo A & Melmed S. Acromegaly. Endocrinology and Metabolism Clinics of North America 2008 37 101-122. (doi:10. 1016/j.ecl.2007.10.002)
11. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB & Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 1999 50 561-567. (doi:10.1046/j.1365-2265.1999.00760.x)
12. Shimon I, Cohen ZR, RamZ & Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001 48 1239-1243 (discussion 1244-1245). (doi:10.1097/00006123-200106000-00008)
13. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P & Christ ER. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochirurgica 2005 147 243-251. (doi:10.1007/s00701-004-0466-2)
14. Scacchi M & Cavagnini F. Acromegaly. Pituitary 2006 9 297-303. (doi:10.1007/s11102-006-0409-4)
15. Sheppard MC. Primary medical therapy for acromegaly. Clinical Endocrinology 2003 58 387-399. (doi:10.1046/j.1365-2265. 2003.01734.x)
16. Cahyanur R, Setyawan W, Sudrajat DG, Setyowati S, Purnamasari D & Soewondo P. Diagnosis and management of acromegaly: giant invasive adenoma. Acta Medica Indonesiana 2011 43 122-128.
17. Ezzat S, Serri O, Chik CL, Johnson MD, Beauregard H, Marcovitz S, Nyomba BL, Ramirez JR & Ur E. Canadian consensus guidelines for the diagnosis and management of acromegaly. Clinical and Investigative Medicine 2006 29 29-39.
18. Imran SA, Fleetwood IG, O'Connell CM, Ransom TP, Mulroy LA, Ur E & Clarke DB. Outcome of stereotactic radiotherapy for patients with uncontrolled acromegaly. Canadian Journal of Neurological Sciences 2009 36 468-474.
19. Bandgar TR, Sarathi V, Shivane V, Bansode N, Menon PS & Shah NS. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. Journal of Postgraduate Medicine 2010 56 7-11. (doi:10.4103/0022-3859.62421)
20. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A & Stewart PM. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. Journal of Clinical Endocrinology and Metabolism 2009 94 1255-1263. (doi:10.1210/jc.2008-1420)
21. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
22. Andersen M, Hagen C, Frystyk J, Schroeder HD & Hagen C. Development of acromegaly in patients with prolactinomas. European Journal of Endocrinology 2003 149 17-22. (doi:10.1530/eje.0.1490017)
23. Bonert VS & Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nature Clinical Practice. Endocrinology & Metabolism 2006 2 408-412. (doi:10.1038/ncpendmet0222)
24. Valenta LJ & Elias AN. Clinical acromegaly with undetectable growth hormone and hyperprolactinemia. Journal of the National Medical Association 1987 79 555, 559-560.
25. Serri O, Chik CL, Ur E & Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ: Canadian Medical Association Journal 2003 169 575-581.
26. Goldman MH & Klinges K. Acromegaly as the amenorrhea-galactorrhea syndrome. New Jersey Medicine: the Journal of the Medical Society of New Jersey 1989 86 887-888.
27. Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A & Colao A. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. Journal of Clinical Endocrinology and Metabolism 2010 95 13-17. (doi:10.1210/jc.2009-1360)
28. Melmed S. Update in pituitary disease. Journal of Clinical Endocrinology and Metabolism 2008 93 331-338. (doi:10.1210/jc.2007-1409)
29. Fideleff HL, Boquete HR, Suárez MG & Azaretzky M. Prolactinoma in children and adolescents. Hormone Research 2009 72 197-205. (doi:10.1159/000236081)
30. Salehi F, Cohen S, Syro LV, Uribe H, Horvath E, Kovacs K & Asa SL. Plurihormonality in pituitary adenomas associated with acromegaly. Endocrine Pathology 2006 17 291-296. (doi:10.1385/EP:17:3:291)
31. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ & Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. European Journal of Endocrinology 2007 156 203-216. (doi:10.1530/eje.1.02326)
32. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 3189-3202. (doi:10.1172/JCI39375)
33. Pawlikowski M, Kunert-Radek J & Radek M. Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Polish Journal of Endocrinology 2010 61 63-66.
34. Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Libè R, Faglia G & Ambrosi B. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. Journal of Neurosurgical Sciences 2001 45 65-69. (Pubitemid 32979938)
35. Mortini P, Losa M, Barzaghi R, Boari N & Giovanelli M. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005 56 1222-1233 (discussion 1233). (doi:10.1227/01.NEU. 0000159647.64275.9D)
36. Kreutzer J, Vance ML, Lopes MB & Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 2001 86 4072-4077. (doi:10.1210/jc.86.9.4072)
37. Bourdelot A, Coste J, Hazebroucq V, Gaillard S, Cazabat L, Bertagna X & Bertherat J. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. European Journal of Endocrinology 2004 150 763-771. (doi:10.1530/eje.0.1500763)
38. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE & Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism 2004 89 495-500. (doi:10.1210/jc.2003-031316)
39. Vierhapper H, Heinze G, Gessl A, Exner M & Bieglmayr C. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism: Clinical and Experimental 2003 52 181-185. (doi:10.1053/meta.2003.50036)
40. Costa AC, Rossi A, Martinelli CE Jr, Machado HR & Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Journal of Clinical Endocrinology and Metabolism 2002 87 3142-3147. (doi:10.1210/jc.87.7.3142)
41. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ & de Herder WW. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. Journal of Clinical Endocrinology and Metabolism 2005 90 6480-6489. (doi:10.1210/jc.2005- 0901)
42. Freda PU, Wardlaw SL & Post KD. Long-term endocrinological follow-up in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 1998 89 353-358. (doi:10.3171/jns.1998.89.3.0353)
43. Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
44. Carmichael JD, Bonert VS, Mirocha JM & Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 523-527. (doi:10.1210/jc.2008-1371)